

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10516705
Filing Date	2004-12-02
First Named Inventor	T. Hara
Art Unit	1645
Examiner Name	tba
Attorney Docket Number	3056 US0P

**U.S. PATENTS**


Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S. PATENT APPLICATION PUBLICATIONS**


Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**


Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
LAR	1	EP 1 466 902	JP		2004-10-13	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

**NON-PATENT LITERATURE DOCUMENTS**



Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

/Lynn Bristol/

05/04/2007

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10516705
Filing Date		2004-12-02
First Named Inventor	T. Hara	
Art Unit	1645	
Examiner Name	tba	
Attorney Docket Number	3056 US0P	

	1	GOTTLIEB, B., et al., "Update of the Androgen Receptor Gene Mutations Database", Human Mutation, (1999), Vol. 14, pages 103-114	<input type="checkbox"/>
	2	HARA, T., et al., "Novel Mutations of Androgen Receptor: A Possible Mechanism of Bicalutamide withdrawal Syndrome", Cancer Research, (2003), Vol. 63, No.1, pages 149-153	<input type="checkbox"/>
	3	KOKONTIS, J., "Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest", Molecular Endocrinology, (1998), Vol. 12, pages 941-953	<input type="checkbox"/>
	4	BENTEL, J., et al., "Androgen Receptor Expression in Primary Prostate Cancers of Lobund-Wistar Rats and in Tumor-Deprived Cell Lines", In Vitro Cellular & Developmental Biology- Animal, (1999), Vol. 35, No. 10, pages 655-662	<input type="checkbox"/>
	5	ZHAO, X., et al., "Two Mutations Identified in the Androgen Receptor of the New Human Prostate Cancer Cell Line MDA PCA 2A", The Journal of Urology, (1999), Vol. 162, pages 2192-2199	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Lynn Bristol/	Date Considered	05/04/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

DT12 Rec'd PCT/PTC 02 DEC 2004

PTO/SB/08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	Based on PCT/JP03/06942
Filing Date	Int'l Filing 02 JUNE 2003
First Named Inventor	Takahito HARA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3056 USOP

Sheet 1 of 2

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Lynn Bristol/	Date Considered	05/04/2007
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**Best Available Copy**

10/516705  
DT10 Rec'd PCT/PTO 02 DEC 2004

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Based on PCT/JP03/06942
		Filing Date	Int'l Filing 02 JUNE 2003
		First Named Inventor	Takahito HARA
		Art Unit	tba
		Examiner Name	tba
Sheet 2 of 2	Attorney Docket Number		3056 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
200	A2	MARIANNE D. SADAR, "Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways", J. Biol. Chem., (1999), pp. 7777-7783, Vol. 274, No. 12	
	A3	J. VELDSCHOLTE, "A Mutation in the Ligand Binding Domain of the Androgen Receptor of Human INCaP Cells Affects Steroid Binding Characteristics and Response to Anti-Androgens", Biochem. Biophys. Res. Commun., (1990), pp. 534-540, Vol. 173, No. 2.	
	A4	M-E TAPLIN, et al., "Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist", Cancer Research, (1999), pp. 2511-2515, Vol. 59, No. 11.	
	A5	M. MARCELLI, et al., "Amino Acid Substitutions in the Hormone-binding Domain of the Human Androgen Receptor Alter the Stability of the Hormone Receptor Complex", J. Clin. Invest. (1994), pp. 1642-1650, Vol. 94, No. 4	
	A6	JAYA P. GADDIPATI, et al., "Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers", Cancer Research, (1994), pp. 2861-2864, Vol. 54, No. 11.	
	A7	KYLLIKKI HAAPALA, et al., "Androgen Receptor Alterations in Prostate Cancer Relapsed During a Combined Androgen Blockade by Orchiectomy and Bicalutamide", Laboratory Investigation, (2001), pp. 1647-1651, Vol. 81, No. 12.	
	A8	JOHN KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Research, (1994), pp. 1566-1573, Vol. 54.	
	A9	YOSHIHISA UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.	

Examiner Signature	/Lynn Bristol/	Date Considered	05/04/2007
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Best Available Copy